Vinpocetine Reduces Carrageenan-Induced Inflammatory Hyperalgesia in Mice by Inhibiting Oxidative Stress, Cytokine Production and NF-κB Activation in the Paw and Spinal Cord

Kenji W. Ruiz-Miyazawa1, Ana C. Zarpelon1, Felipe A. Pinho-Ribeiro1, Gabriela F. Pavão-de-Souza2, Rubia Casagrande2, Waldiceu A. Verri, Jr1*

1 Departamento de Ciências Patológicas, Universidade Estadual de Londrina, Londrina, Paraná, Brasil, 2 Departamento de Ciências Farmacêuticas, Universidade Estadual de Londrina Londrina, Hospital Universitário, Londrina, Paraná, Brasil

* waverri@uel.br

Abstract

Vinpocetine is a safe nootropic agent used for neurological and cerebrovascular diseases. The anti-inflammatory activity of vinpocetine has been shown in cell based assays and animal models, leading to suggestions as to its utility in analgesia. However, the mechanisms regarding its efficacy in inflammatory pain treatment are still not completely understood. Herein, the analgesic effect of vinpocetine and its anti-inflammatory and antioxidant mechanisms were addressed in murine inflammatory pain models. Firstly, we investigated the protective effects of vinpocetine in overt pain-like behavior induced by acetic acid, phenyl-p-benzoquinone (PBQ) and formalin. The intraplantar injection of carrageenan was then used to induce inflammatory hyperalgesia. Mechanical and thermal hyperalgesia were evaluated using the electronic von Frey and the hot plate tests, respectively, with neutrophil recruitment to the paw assessed by a myeloperoxidase activity assay. A number of factors were assessed, both peripherally and in the spinal cord, including: antioxidant capacity, reduced glutathione (GSH) levels, superoxide anion, tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) levels, as well as nuclear factor kappa B (NF-κB) activation. Vinpocetine inhibited the overt pain-like behavior induced by acetic acid, PBQ and formalin (at both phases), as well as the carrageenan-induced mechanical and thermal hyperalgesia and associated neutrophil recruitment. Both peripherally and in the spinal cord, vinpocetine also inhibited: antioxidant capacity and GSH depletion; increased superoxide anion; IL-1β and TNF-α levels; and NF-κB activation. As such, vinpocetine significantly reduces inflammatory pain by targeting oxidative stress, cytokine production and NF-κB activation at both peripheral and spinal cord levels.
Introduction

Modern lifestyle has raised life expectancy, but also increased the incidence of chronic diseases [1], consequently increasing chronic pharmaceutical usage. Inflammation is a hallmark of many chronic diseases, with the long-term use of steroids and/or non-steroid anti-inflammatory drugs leading, in many instances, to hormonal side effects and gastric lesions [2,3]. As such, the development of novel anti-inflammatory drugs and treatment approaches is urgently needed.

Vinpocetine (ethyl apovincamine-22-oate) is a synthetic ethyl ester of the alkaloid apovincamine, which is isolated from the leaves of Vinca minor, commonly known as the lesser periwinkle [4]. Vinpocetine has been used in the management of various cerebrovascular disorders, including cerebral infarction and residual cerebral hemorrhage [5], as well as in the treatment of cognitive disorders [4]. Importantly, no significant vinpocetine side effects have been reported [6], whilst its positive effects on cognition are even apparent in health volunteers [7].

As well as being a phosphodiesterase-1 inhibitor [8], the emerging literature suggests that vinpocetine also has potent anti-inflammatory effects via phosphodiesterase-1-independent inhibition of nuclear factor kappa B (NF-κB) signaling and the production of pro-inflammatory cytokines, such as IL-1β and TNF-α [9]. Moreover, it has been shown that vinpocetine inhibits neuronal reactive oxygen species (ROS) production [10,11], thereby decreasing oxidative stress [12]. The pro-inflammatory cytokines TNF-α and IL-1β, in conjunction with ROS, such as the superoxide anion radical, are important peripheral and spinal hyperalgesic mediators and therefore represent relevant targets for analgesic drug development [13,14]. An analgesic role for vinpocetine is supported by its clinical utility in a wide range of neuroinflammatory human diseases, including multiple sclerosis [15], intracranial birth trauma-induced seizures [16], and chronic brain ischemia [17].

Data pertinent to the analgesic effect of vinpocetine show that it inhibits neuronal tetrodotoxin-resistant NaV1.8 sodium channel currents and sodium current-induced calcium influx [18,19], with intraperitoneal (i.p) administration of vinpocetine reducing acetic acid-induced visceral nociception, which was potentiated by muscarinic, adrenergic or opioid receptor blockade and dependent on adenosine receptors [20]. Vinpocetine also inhibits formalin-induced paw flinching, accompanied by inhibition of c-fos expression in the ipsilateral dorsal horn, when perineurally administered [21]. It has been also suggested that vinpocetine reduces neuropathic pain by blocking retrograde axoplasmic transport of nerve growth factor [21]. However, the peripheral and spinal effects of vinpocetine in inflammatory hyperalgesia and its mechanisms of action require investigation. Given the above literature, the present study aimed to investigate the effects of orally administered vinpocetine in a murine inflammatory pain model. In addition, we also assessed whether the analgesic effects of vinpocetine were related to peripheral and spinal inhibition of oxidative stress and cytokine production, as well as NF-κB activity.

Material and Methods

Animals

Male Swiss mice (25–30 g) from the Universidade Estadual de Londrina, Londrina, Paraná, Brazil, were used in this study. Mice were housed in standard clear plastic cages with free access to food and water with a light/dark cycle of 12/12h at a constant temperature of 21°C. All behavioral testing was performed between 9 a.m. and 5 p.m. in a temperature-controlled (21°C) room. Animal care and handling procedures were approved by the Ethics Committee of the
Universidade Estadual de Londrina (process number 13278.2011.3). All efforts were made to minimize animal suffering and to reduce the number of animals used.

Drugs and stimuli

Materials were obtained from the sources as follows: vinpocetine (Marjan Indústria & Comércio Ltda, São Paulo, Brazil), carrageenan (FMC Corp, Philadelphia, PA, United States), acetic acid and formaldehyde (Mallinckrodt Baker, S.A., Mexico, Mexico City), phenyl-p-benzoquinone (Sigma Chemical Company, St. Louis, MO).

Experimental procedures

Mice received per oral (p.o.) treatment with vinpocetine (1, 3, 10, or 30 mg/kg) 1 h before the inflammatory stimulus. The dose of inflammatory stimuli was based on previous studies in our laboratory [22–25]. The writhing response was evaluated during the 20 min after i.p. injection of phenyl-p-benzoquinone (PBQ) (1890 μg/kg) or acetic acid 0.6% (10 mL/kg). The number of formalin (formalin 1.5%, 25 μL/paw)-induced flinches was evaluated during the 30 min after injection. Mechanical and thermal hyperalgesia was evaluated 1–9 h after carrageenan (100 μg, 25 μL, i.pl.), with neutrophil recruitment in paw skin indicated by myeloperoxidase (MPO) activity assay 9 h after carrageenan injection. IL-1β, TNF-α, total NF-κB and phosphorylated NF-κB levels were measured in the paw skin and spinal cord 3 h after carrageenan injection. The experimenters evaluating the recorded responses were blind as to specific treatments being assessed.

Writing response tests

The PBQ and acetic acid-induced writhing models were performed as previously described [25]. PBQ (DMSO 2%, v/v in saline), acetic acid (0.6%, v/v in saline) or vehicle were injected into the peritoneal cavities of mice pre-treated with vinpocetine (1–30 mg/kg, p.o.). The intensity of overt pain-like behavior is expressed as the cumulative number of writhings over 20 minutes after stimulus injection.

Formalin test

The number of paw flinches were determined between 0–30 minutes after 25 μL formalin i.pl. injection, as previously described [26]. The period was divided into intervals of 5 minutes, and clearly demonstrated the presence of the first (0–5 min) and second (15–30 min) phase, which are characteristic of the test. Results are presented as the number of flinches in the first and second phases.

Mechanical hyperalgesia test

Mechanical hyperalgesia was measured by an electronic version of von Frey filaments [27]. The test consisted of evoking a hind paw reflex with a hand-held force transducer (electronic anesthesiometer; Insight, Ribeirao Preto, SP, Brazil). After the paw withdrawal, the intensity of the pressure was recorded automatically, with values being averaged across three measurements. Mice were tested before (basal) and after stimulus injection. The results are expressed as delta (Δ) withdrawal threshold (in g), calculated by subtracting the basal mean measurements from the mean measurements obtained at 1, 3, 5, 7, or 9 h after carrageenan i.pl. injection.
Hot plate test
Mice were placed on a hot plate apparatus (IITC Life Science Inc. Woodland Hills, CA) maintained at 55°C. The reaction time was indicated by the time for the animal to jump or lick their paws. A maximum latency (cut-off) was set at 30 s to avoid tissue damage [28].

MPO Activity
Myeloperoxidase (MPO) activity, an indicator of neutrophil recruitment to the paw skin, was evaluated by the MPO kinetic-colorimetric assay [29]. Samples were homogenized using a tissue-tearor (Biospec) in ice-cold K$_2$HPO$_4$ buffer (400 μL, 50 mM, pH 6.0) containing HTAB (0.5% weight/volume), and the homogenates were centrifuged (16100 g × 2 min × 4°C). The supernatants (30 μL) were mixed with K$_2$HPO$_4$ buffer (200 μL, 50 mM, pH 6.0) containing o-dianisidine dihydrochloride (0.0167%, w/v) and hydrogen peroxide (0.05%, v/v). The absorbance was determined after 5 min at 450 nm (Multiskan GO Microplate Spectrophotometer, Thermo Scientific, Vantaa, Finland). The results of MPO activity are expressed as the number of neutrophils per mg of tissue by using a standard curve of neutrophils (196–400000 cells).

ABTS and FRAP assays
The ability of samples to resist oxidative damage was determined by their free radical scavenging (ABTS [2,2’-Azinobis-3-ethylbenzothiazoline 6-sulfonic acid] assay) and ferric reducing (FRAP assay) properties. The tests were adapted to a 96-well microplate format as previously described [30]. Plantar tissue samples were collected 3 h after carrageenan i.pl. injection (100 μg, 25 μL) and homogenized immediately in ice-cold KCl buffer (500 μL, 1.15% w/v). The homogenates were centrifuged (200 g × 10 min × 4°C), and the supernatants were used in both assays. Diluted ABTS solution (200 μL) was mixed with 10 μL of sample in each well. After 6 min of incubation at 25°C, the absorbance was measured at 730 nm. For FRAP assay, the supernatants (10 μL) were mixed with the freshly prepared FRAP reagent (150 μL). The reaction mixture was incubated at 37°C for 30 min, and the absorbance was measured at 595 nm (Multiskan GO Thermo Scientific). The results of ABTS and FRAP assays were equated against a standard Trolox curve (0.02–20 nmol).

GSH levels measurement
Samples of paw skin and spinal cord were collected and maintained at −80°C for at least 48 h. The sample was homogenized with 200 μL of 0.02 M EDTA. The homogenate was mixed with 25 μL of trichloroacetic acid 50% and was homogenized three times over 15 min. The mixture was centrifuged (15 min x 1500 g x 4°C). The supernatant was added to 200 μL of 0.2 M TRIS buffer, pH 8.2, and 10 μL of 0.01M DTNB. After 5 min, the absorbance was measured at 412 nm (Multiskan GO, Thermo Scientific) against a blank reagent with no supernatant. A standard GSH curve was formed. The results are expressed as GSH per mg of protein [31].

Superoxide anion production
The quantification of superoxide anion production in tissue homogenates (10 mg/mL in 1.15% KCl) was performed using the nitroblue tetrazolium (NBT) assay [32]. Briefly, 50 μL of the homogenate was incubated with 100 μL of NBT (1 mg/mL) in 96-well plates at 37°C for 1 h. The supernatant was then carefully removed and the reduced formazan solubilized by adding 120 μL of KOH 2M and 140 μL of DMSO. The NBT reduction was measured at 600 nm (Multiskan GO, Thermo Scientific). The tissue weight was used for data normalization.
Cytokine measurement

Paw skin and spinal cord (L4-L6) samples were homogenized in 500 μL of buffer containing protease inhibitors, with IL-1β and TNF-α levels being determined as previously described by an enzyme-linked immunosorbent assay (ELISA) using eBioscience kits [31]. The results are expressed as picograms (pg) of cytokine/100 mg of tissue.

NF-κB activity

The paw skin samples were collected and homogenized in ice-cold lysis buffer (Cell Signaling). The homogenates were centrifuged (200 g × 10 min × 4°C), with the supernatants used to assess the levels of phosphorylated and total NF-κB p65 subunit by ELISA using PathScan kits (Cell Signaling) according to the manufacturer’s directions. The results represent the sample ratio (total p65/phospho-p65) measured at 450 nm (Multiskan GO Thermo Scientific).

Data analyses

Results are presented as means +/- SEM of measurements made on 6 mice per group per experiment and are representative of two independent experiments. Two-way ANOVA was used to compare the groups and doses at all times when the parameters were measured at different times after the stimulus injection. The analyzed factors were treatments, time, and time versus treatment interaction. One-way ANOVA followed by Tukey’s t-test was performed for each time-point. P < 0.05 was considered significant.

Results

Vinpocetine inhibits the acetic acid- and PBQ-induced writhing responses, as well as the formalin-induced paw flinches

In the first series of experiments, the analgesic effect of vinpocetine was evaluated in acetic acid-, PBQ-, and formalin-induced overt pain-like behaviors. Mice were treated with vinpocetine (1, 3, 10, and 30 mg/kg p.o.) or vehicle (saline) 1 hour before acetic acid injection. Vinpocetine, at the doses of 3–30 mg/kg, inhibited the acetic acid-induced writhing response (Fig. 1A). At 1 mg/kg, vinpocetine showed no effect. A dose of 10 mg/kg of vinpocetine was selected for the following experiments, given that it achieved an inhibition of 56%, which was statistically similar to its inhibitory effect at 30 mg/kg. At a dose of 10 mg/kg, vinpocetine inhibited the PBQ-induced writhing response (81%) (Fig. 1B), and both the first (36%) and second phases (54%) of formalin-induced paw flinches (Fig. 1C).

Vinpocetine inhibited carrageenan-induced hyperalgesia and MPO activity

Mice were treated with vinpocetine (3, 10, or 30 mg/kg, p.o.) 1 h before carrageenan (100 μg, 25 μL) i.pl. injection, with mechanical (Fig. 2A) and thermal (Fig. 2B) hyperalgesia being evaluated at the indicated time points. After the last measurement (9 h), mice were euthanized and paw skin samples were collected to determine MPO activity (Fig. 2C). Carrageenan induced significant mechanical hyperalgesia, which was not affected by 3 mg/kg of vinpocetine (Fig. 2A). However, 10 mg/kg of vinpocetine significantly inhibited carrageenan-induced mechanical hyperalgesia at 5–9 h, with significant differences when compared to vinpocetine 3 mg/kg at 7 and 9 h. The dose of 30 mg/kg of vinpocetine inhibited carrageenan-induced mechanical hyperalgesia between 3 and 9 h (up to 78%), with significant differences compared to the lower doses of vinpocetine between 5 and 9 h. Vinpocetine at 30 mg/kg abolished
carrageenan-induced thermal hyperalgesia (up to 100%) (Fig. 2B). Furthermore, 10 mg/kg of vinpocetine significantly inhibited carrageenan-induced thermal hyperalgesia at 5 h, being significantly more effective when compared to the lower dose of vinpocetine (Fig. 2B). MPO activity was reduced by vinpocetine at 30 mg/kg (69%) but not at lower vinpocetine doses (Fig. 2C). Given the results shown in Fig. 2, a vinpocetine dose of 30 mg/kg was selected for the following experiments.

Fig 1. Vinpocetine inhibits overt pain-like behavior. Panel A: mice were treated with vinpocetine (1, 3, 10, and 30 mg/kg, p.o.) or vehicle (saline) 1 h before acetic acid i.p. injection (0.6% v/v, diluted in saline). Panels B-C: mice were treated with vinpocetine (30 mg/kg, p.o.) or vehicle (saline) 1 h before i.p. injection of phenyl-p-benzoquinone (PBQ, 1890 μg/kg in DMSO 2%, v/v, diluted in saline, panel B), or i.pl. injection of formalin (25 μL of 1.5% formalin, v/v in saline, panel C). The cumulative number of writhing was evaluated over 20 min (Panels A-B) and total number of paw flinches (Panel C) were evaluated over 30 min. Results are presented as means ± SEM of 6 mice per group per experiment, and are representative of 2 separate experiments. *P < 0.05 compared with the saline group; #P < 0.05 compared to the vehicle group; and fP < 0.05 compared to the vehicle group and the 1 mg/kg vinpocetine dose. One-way ANOVA followed by Tukey’s t test.

Fig 2. Vinpocetine inhibits carrageenan-induced hyperalgesia and myeloperoxidase (MPO) activity. Mice were treated with vinpocetine (3, 10 or 30 mg/kg, p.o.) or vehicle (saline) 1 h before carrageenan (100 μg, 25 μL) i.pl. injection. Mechanical (Panel A) and thermal (Panel B) hyperalgesia were assessed at indicated time points after carrageenan administration using the electronic von Frey and hot plate tests, respectively. Myeloperoxidase (MPO) activity was determined in samples collected 9 h after carrageenan injection. Results are presented as means ± SEM of 6 mice per group per experiment, and are representative of 2 separate experiments. *P < 0.05 compared to saline group; **P < 0.05 compared with vehicle group; ***P < 0.05 compared with the dose of 3 mg/kg of vinpocetine; and ****P < 0.05 compared with the doses of 10 and 30 mg/kg of vinpocetine. One-way ANOVA followed by Tukey’s t test.
Vinpocetine inhibits carrageenan-induced reduction of ABTS free radical scavenging ability and ferric reducing antioxidant power (FRAP)

Mice were treated with vinpocetine (30 mg/kg, p.o.) 1 h before injection with carrageenan (100 μg, 25 μL, i.pl.) injection. Paw skin (Panels A and B) and spinal cord (Panels D and E) samples were collected 3 h after carrageenan injection for measurement of ABTS (Panels A and C) and FRAP (Panels B and D) assays. Results are presented as means ± SEM of 6 mice per group per experiment, and are representative of 2 separate experiments. *P < 0.05 compared with saline group; and #P < 0.05 compared with vehicle group. One-way ANOVA followed by Tukey’s t test.

doi:10.1371/journal.pone.0118942.g003

Vinpocetine inhibits carrageenan-induced reduction of ABTS free radical scavenging ability and ferric reducing antioxidant power (FRAP)

Mice were treated with vinpocetine (30 mg/kg, p.o.) 1 h before injection with carrageenan (100 μg, 25 μL, i.pl). Mice were terminally anesthetized 3 h after the injection, with samples from the paw skin and spinal cord (L4-L6) being collected to evaluate the ABTS free radical scavenging ability and FRAP. Carrageenan reduced ABTS scavenging ability (Fig. 3A and 3C) and FRAP (Fig. 3B and 3D) in the paw skin and spinal cord samples. Vinpocetine treatment attenuated the carrageenan-induced decrease in ABTS scavenging ability (54 and 60%) and FRAP (37 and 100%) in paw skin and spinal cord samples, respectively.
Treatment with vinpocetine attenuated the carrageenan-induced GSH depletion and superoxide anion production

Mice were treated with vinpocetine (30 mg/kg, p.o.) 1 h before i.pl. injection of carrageenan. Samples of cutaneous paw skin and spinal cord (L4-L6) were collected 3 h after carrageenan injection for GSH measurement (Fig. 4A and 4C, respectively). Carrageenan induced a significant GSH decrease in the paw skin (Fig. 4A) and spinal cord (Fig. 4B), which was inhibited by vinpocetine (99% and 50%, respectively). Carrageenan also induced superoxide anion
Vinpocetine inhibits carrageenan-induced IL-1β and TNF-α production in the paw skin and spinal cord, which were abolished by vinpocetine 30 mg/kg treatment.

Vinpocetine inhibits carrageenan-induced IL-1β and TNF-α production in the paw skin and spinal cord

Mice were treated with vinpocetine (30 mg/kg, p.o.) 1h before carrageenan i.pl. injection. Samples from the paw skin and spinal cord tissue (L4-L6) were collected 3 h after carrageenan injection for IL-1β and TNF-α measurement (Fig. 5). Carrageenan significantly increased IL-1β

![Graphs showing IL-1β and TNF-α production in paw skin and spinal cord with vinpocetine treatment.](image-url)
and TNF-α levels in paw skin (Fig. 5A and 5B, respectively) and spinal cord (Fig. 5C and 5D, respectively), which were attenuated by vinpocetine treatment (49% and 73%, and 65% and 64%, respectively).

Vinpocetine attenuates peripheral and spinal NF-κB activation induced by carrageenan

The levels of total and phosphorylated NF-κB p65 subunits were evaluated in samples from the paw skin and spinal cord (L4-L6). Mice were treated with vinpocetine (30 mg/kg) 1 h before carrageenan i.pl. injection, with the samples being collected 3 h after injection. Vinpocetine (Fig. 5) attenuated carrageenan-induced NF-κB activation in the paw skin (Fig. 6A, 43%) and spinal cord (Fig. 6B, 83%) samples.

Discussion

Increased pain sensitivity is a common feature of the inflammatory response and occurs after tissue injury. The peripheral sensitization is triggered by NF-κB-related pro-inflammatory mediators, including the cytokines TNF-α and IL-1β [14,33,34], as well as ROS such as the superoxide anion radical [35]. In addition to their role in the inflammatory response, these mediators can act directly on their receptors or targets expressed by peripheral terminals of nociceptors to reduce pain thresholds, leading to inflammatory pain and hyperalgesia [36,37]. Moreover, they induce the recruitment of neutrophils, leading to the further enhancement of hyperalgesic mediators, such as prostaglandin E2 (PGE2) and the superoxide anion [33,35]. Consequently, inhibiting the production of such hyperalgesic mediators is an important pain control target [14,34]. It is important to note that in a number of diseases inflammatory hyperalgesia is the major symptom responsible for reducing quality of life [38,39], which is often further reduced by the side effects occurring from the chronic use of corticosteroids and non-steroid anti-inflammatory drugs [2,3]. In this study, we described the anti-hyperalgesic effects
of vinpocetine, showing that its mechanism of action targets peripheral and spinal cord oxidative stress, TNF-α, IL-1β and NF-kB activation.

Vinpocetine is a safe nootropic agent that is widely used to improve memory and to treat neurological diseases. Vinpocetine has a low oral bioavailability, achieving about 0.7% absorption in humans [40], although its absorption may increase to 60–100% in non-fasted individuals [41]. Radio-labeled vinpocetine (10 mg tablet) administered orally to humans appears in the blood and brain shortly after administration and increases continuously for at least 120 and 100 min, respectively [40]. These being the maximal periods investigated in each tissue. [40]. Therefore, orally administrated vinpocetine is rapidly distributed throughout the entire body explaining its therapeutic use and commercialization. Preclinical studies using acetic acid- and formalin-induced overt pain-like behaviors shows vinpocetine to exert analgesic effects when administered via i.p or perineural routes, respectively [20,21]. Our results support such research, showing that vinpocetine exhibits analgesic effects in acetic acid-, PBQ- and formalin-induced overt pain-like behaviors, even when administered orally, thereby confirming its applicability as an orally active analgesic in such models. In fact, the potential therapeutic importance of vinpocetine has generated a large number of studies that have attempted to improve its absorption [42], thereby allowing a reduced dose for therapeutic effect and/or increased efficacy. Importantly, these animal models, except the first phase of formalin test, depend on cytokine production to induce inflammation and pain [25,43], suggesting that inflammatory pain attenuation by vinpocetine depends, at least in part, on decreasing the production of such mediators.

Recent work shows vinpocetine to afford protection in numerous inflammatory conditions, including atherosclerosis [44,45], lung inflammation [9], macular degeneration [46] and cerebral ischemia–reperfusion injury [47]. In these studies, the vinpocetine anti-inflammatory effect was at least partly driven by its attenuation of NF-κB activity and its inflammatory products, such as TNF-α and IL-1β. Carrageenan and lipopolysaccharide (LPS) from gram-negative bacteria activate TLR4/MyD88 signaling, thereby triggering NF-κB activation and the cytokines, including TNF-α and IL-1β, which are responsible for pain and inflammation [48–50]. Targeting TLR4/MyD88, NF-κB, TNF-α and IL-1β reduces carrageenan- and LPS-induced hyperalgesia [14,33,51]. Therefore, we reason that the attenuation of NF-κB activity, including by decreasing TNF-α and IL-1β production, is an important determinant of vinpocetine’s analgesic effects.

NF-κB heterodimer p50/p65 activates the transcription of a large number of genes, many of which are key mediators of the inflammatory response [52–54]. Inhibiting NF-κB signaling impairs neutrophil recruitment during acute inflammation by reducing the expression of NF-κB target genes, including pro-inflammatory cytokines and chemokines [55–57]. TNF-α and IL-1β are crucial mediators in the recruitment of neutrophils after tissue injury by directly chemoattracting neutrophils and activating resident inflammatory cells, which further amplifies the production of chemotactic molecules [56–59]. Neutrophils, in turn, play an important role in carrageenan-induced hyperalgesia as these cells provide an important source of the superoxide anion and other hyperalgesic mediators, such as PGE₂ [33,60,61]. In this study, we found that vinpocetine reduced neutrophil recruitment, as assessed by MPO activity. Neutrophils produce large amounts of the superoxide anion, thereby contributing to many of the deleterious effects of inflammation, such as oxidative stress, tissue injury and hyperalgesia [33,60,61]. In agreement with this, we showed vinpocetine to also inhibit the carrageenan-induced peripheral decrease in antioxidant capacity and GSH levels. Previous work, in a rat demyelination model, showed vinpocetine to reduce oxidative stress [12], although, the association of oxidative stress with increased pro-inflammatory cytokines was not addressed in this study. Considering the dependency of carrageenan-induced hyperalgesia on not only TNF-α and IL-1β
production [33], but also oxidative stress [35,62], and the peripheral inhibition of these cytokines and oxidative stress by vinpocetine treatment reported here, our results serve to better integrate previous work that separately described the analgesic, anti-inflammatory and antioxidant effects of vinpocetine [9,11,12,20,21,45–47].

Inflammation-induced peripheral nociceptor sensitization leads to increases in nociceptor inputs and in nociceptive stimuli transmission. This enhanced afferent activity, in turn, induces long-lasting increases in the excitability of spinal cord neurons and contributes to inflammatory pain hypersensitivity [63]. This central sensitization shares some mechanisms with the peripheral sensitization process. At the level of the spinal cord, as well as in dorsal root ganglion, glial cells act as sentinels of neuronal activity and damage. Glial cells produce inflammatory mediators in response to raised glutamate, as occurs during increased neurotransmission.

Among these mediators, TNF-α, IL-1β and the superoxide anion act synergistically to sensitize nociceptive neurons [63,64]. In line with this, we found that vinpocetine also attenuated NF-κB activation, as well as TNF-α, IL-1β and oxidative stress at the spinal cord level, which may represent an important anti-hyperalgesic mechanism in the spinal cord. In line with this hypothesis, vinpocetine can inhibit glutamate signaling [65] as well as the calcium and sodium channel-mediated release of glutamate from nerve endings [18,66]. Vinpocetine also affords neuroprotection by reducing NF-κB expression, and IL-1β and TNF-α production, by microglia cells [9,11,18]. The central anti-inflammatory effect of vinpocetine was further shown by its decrease in hippocampal TNF-α and IL-1β production in a preclinical study of the pro-convulsive agents, 4-aminopyridine, pentylenetetrazole and pilocarpine, where vinpocetine inhibited cytokine production induced by increased neuronal activity [67].

The antioxidant effects of vinpocetine described in cerebral isolated nerve endings are similar to those of α-tocopherol, a classical antioxidant [10]. Considering its high permeability through the blood-brain barrier [68], it is possible that vinpocetine is acting at the spinal level to inhibit NF-κB activation, pro-inflammatory mediator production and oxidative stress, thereby preventing the resulting central sensitization. Alternatively, given that peripheral carrageenan injection induces CX3CL1 production by neurons, which activates satellite glial cells to release TNF-α and IL-β around the dorsal root ganglion that contributes to nociceptor sensitization [69], the peripheral inhibition of inflammation by vinpocetine may result in reduced activation (oxidative stress, cytokine production, NF-κB activation) in the spinal cord.

Additionally, vinpocetine has direct neuronal effects that could also reduce the nociceptive inputs, including blocking the retrograde axoplasmic transport of nerve growth factor, which is proposed as its analgesic mechanism of action in neuropathic pain [21]. Vinpocetine also blocks NaV1.8 sodium currents [19,70–73], being another means whereby it may act directly to inhibit nociceptor activation. In fact, we observed that vinpocetine reduced the first phase (0–5 min) of the formalin test, which is considered a neurogenic phase [43,74], with the second phase depending on hyperalgesic inflammatory mediators. One important step during inflammation-triggered hyperalgesia is increased intracellular calcium levels in nociceptors [75], which vinpocetine may achieve by reducing sodium currents-induced intracellular calcium level increases, as shown by previous data in rat hippocampal pyramidal cells [76]. Moreover, systemic treatment with vinpocetine delays the reaction time of naïve mice in the hot plate test [20] and reduces oxidative stress levels in rat brain [12], suggesting that supraspinal mechanisms are also involved. Such data is in concordance with the more pronounced effects of vinpocetine to reduce thermal hyperalgesia, as reported here.

Vinpocetine is also known as a phosphodiesterase-1 (PDE-1) inhibitor, which degrades cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) [77]. Increasing cGMP levels is an analgesic mechanism of nitric oxide donors, as well as of analgesics in clinical use [78,79]. TNF-α and IL-1β induce PGE2 production, which is ultimately
responsible for nociceptor sensitization and hyperalgesia development in the carrageenan model [80,81]. PGE2 activates EP3 and EP4 receptors increasing cAMP and PKA to induce hyperalgesia [82]. Moreover, PKCe is also activated by increased cAMP levels in nociceptive neurons and contributes to the hyperalgesia induced [83]. As such, increasing neuronal cAMP levels would not be likely to contribute to the analgesic effects of vinpocetine. On the other hand, increasing cAMP in tissue resident cells such as macrophages can reduce inflammation by, for instance, inducing receptor shedding [84] and inhibiting cytokine production [85]. Additionally, it must be pointed out that vinpocetine also directly activates the large-conductance calcium-activated potassium channels (BKCa) in neurons and neuroendocrine cells, which contribute to membrane hyperpolarization and thus also represents a possible analgesic mechanism of vinpocetine [86]. As such, it remains to be determined as to the contribution of PDE-1 and BKCa channels to the analgesic effect of vinpocetine.

It is noteworthy that vinpocetine inhibits TNF-α- and LPS-induced inflammatory mediators and NF-κB activation by targeting IκB kinase (IKK) activity in a variety of cell lines, as well as in models of lung inflammation [9]. In this same study, IC86340, a highly selective PDE-1 inhibitor did not affect TNF-α-induced NF-κB activation or IKK activity. Furthermore, TNF-α-induced IKK activity, IκB phosphorylation and IκB degradation were not affected by nifedipine (Ca2+ channel blocker), EGTA (extracellular Ca2+ chelator), 1,2-bis(o-Aminophenoxy)ethane-N,N,N',N'-tetraacetic Acid Tetra(acetoxymethyl) Ester (BAPTA/AM; an intracellular Ca2+ chelator) and tetrodotoxin (Na+ channel inhibitor) in rat vascular smooth muscle cells [9]. Additionally, although there is evidence that vinpocetine inhibits PDE-4, it did not inhibit PDE-4 as effectively as rolipram, a classical PDE-4 inhibitor with anti-inflammatory effects [9,87]. Therefore, despite reports indicating that vinpocetine inhibits PDE-1, PDE-4, Ca2+ and Na+ channels [18,19,37,66,71–73,88], none of these mechanisms participated in the anti-inflammatory effects of vinpocetine that involve targeting IKK activity that consequently attenuates NF-κB activity, suggesting that there may be other novel vinpocetine mechanism(s) of action [9].

Finally, it is important to highlight that vinpocetine exhibits gastric protective [89] and antidepressant [20,90] effects, suggesting that vinpocetine is a highly promising and safe candidate treatment for the clinical management of inflammation and pain, thereby improving patients’ quality of life.

Conclusions

Vinpocetine inhibited inflammatory pain by targeting NF-κB activation and the NF-κB-driven transcriptional consequences, including cytokine production and oxidative stress, both peripherally in the paw skin and centrally in the spinal cord. Therefore, given that vinpocetine is already in clinical use as a nootropic drug with a good safety profile, it will be important to further investigate its utility and mechanism(s) of action as an analgesic.

Acknowledgments

The authors would like to thank the technical support of Talita P. Domiciano. The authors would like to thank George Anderson, CRC Scotland & London for English editing services.

Author Contributions

Conceived and designed the experiments: RC WAVJ. Performed the experiments: KWRM ACZ FAPR GFPS. Analyzed the data: KWRM ACZ FAPR GFPS RC WAVJ. Contributed reagents/materials/analysis tools: RC WAVJ. Wrote the paper: KWRM FAPR RC WAVJ. Drafting the article or revising it critically for important intellectual content: KWRM ACZ FAPR.
GFPS RC WAVJ. Final approval of the version to be published: KWRM ACZ FAPR GFPS RC WAVJ. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: KWRM ACZ FAPR GFPS RC WAVJ.

References

1. Ehlers S, Kaufmann SH. Infection, inflammation, and chronic diseases: consequences of a modern lifestyle. Trends Immunol. 2010; 31: 184–190. doi: 10.1016/j.it.2010.02.003 PMID: 20399709

2. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009; 103: 975–994. doi: 10.1016/j.rmed.2009.01.003 PMID: 19372037

3. Süleyman H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacoepol Rep. 2007; 59: 247–258. PMID: 17652824

4. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane database Syst Rev. 2003;CD0013119.

5. Horváth S. [The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion]. Orv Hetil. 2001; 142: 383–389. PMID: 11150485

6. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987; 35: 425–430. PMID: 3553281

7. Subhan Z, Hindmarch I. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol. 1985;28: 567–571. PMID: 3899677

8. Van Staveren WC, Markerink-van Ittersum M, Steinbusch HW, de Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res. 2001; 888: 275–286. PMID: 11150485

9. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS et al. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but POE-independent mechanism. Proc Natl Acad Sci U S A. 2010; 107: 9795–9800. doi: 10.1073/pnas.0914414107 PMID: 20448200

10. Herrera-Mundo N, Sitges M. Vinpocetine and α-tocopherol prevent the increase in DA and oxidative stress induced by 3-NPA in striatum isolated nerve endings. J Neurochem. 2013; 124: 233–240. doi: 10.1111/jnc.12082 PMID: 23121080

11. Zhao YY, Yu JZ, Li QY, Ma CG, Lu CZ, Xiao BG. TSPO-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation. Neuron Glia Biol. 2011; 7: 187–197. doi: 10.1017/ S1740925X12000129 PMID: 22874716

12. Abdel-Salam OM, Khadrawy YA, Salem NA, Sleem AA. Oxidative stress in a model of toxic demyelination in rat brain: the effect of piracetam and vinpocetine. Neurochem Res. 2011; 36: 1062–1072. doi: 10.1007/s11064-011-0450-1 PMID: 21448596

13. Salvemini D, Little JW, Doyle T, Neumann WL. Roles of reactive oxygen and nitrogen species in pain. Free Radic Biol Med. 2011; 51: 951–966. doi: 10.1016/j.freeradbiomed.2011.01.026 PMID: 21277369

14. Verri WA Jr, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacoepol Ther. 2006; 112: 116–138. PMID: 16730375

15. Suzumura A, Nakamuro T, Tamaru T, Takayanagi T. Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors. Mult Scler. 2000; 6: 56–56. PMID: 10694847

16. Dutov AA, Gaivanitsa GA, Volkova VA, Sukhanova ON, Lavrishcheva TG, Petrov AP. [Cavinton in the prevention of the convulsive syndrome in children after birth injury]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991; 91: 21–22. PMID: 1665643

17. Tabeeva GR, Azimova LuE. [The multimodal strategy for the neuroprotection in stroke: results of the Russian multicenter clinical-epidemiological program SOKOL]. Zh Nevropatol Psikhiatr Im S S Korsakova. 2012; 112: 26–30. PMID: 23390650

18. Sitges M, Guereros A, Nekrossof V. Effects of carbamazepine, phenytoin, valproic acid, oxcarbazine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacology. 2007; 53: 854–862. PMID: 17904592

19. Zhou X, Dong XW, Crona J, Maguire M, Priestley T. Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels. J Pharmaco Exp Ther 306: 498–504. PMID: 12730276
20. Abdel Salam OM (2006) Vinpocetine and piracetam exert antinociceptive effect in visceral pain model in mice. Pharmacol Reports. 2003; 58: 680–691.

21. Csillik B, Mihály A, Krísztín-Péva B, Farkas I, Knyihár-Csillik E. Mitigation of nociception via transglionic degenerative atrophy: possible mechanism of vinpocetine-induced blockade of retrograde axoplasmic transport. Ann Anat. 2008; 190: 140–145. doi: 10.1016/j.aanat.2007.10.002 PMID: 18413267

22. Borghi SM, Carvalho TT, Staurenghi-Ferrari L, Hohmann MS, Pinge-Filho P, Casagrande R, Verri WA Jr. Vitexin Inhibits Inflammatory Pain in Mice by Targeting TRPV1, Oxidative Stress, and Cytokines. J Nat Prod. 2013; 76: 1141–1149. doi: 10.1021/nl304022w PMID: 23742617

23. Cunha TM, Verri WA Jr, Fukada SY, Guerrero AT, Santodomingo-Garzón T, Poole S et al. TFN-alpha and IL-1β mediate inflammatory hypernociception in mice triggered by B1 but not B2 kinin receptor. Eur J Pharmacol. 2007; 573: 221–229. PMID: 17669394

24. Navarro SA, Serafim KG, Mizokami SS, Hohmann MS, Casagrande R, Verri WA Jr. Analgesic activity of piracetam: Effect on cytokine production and oxidative stress. Pharmacol Biochem Behav. 2013; 105: 183–192. doi: 10.1016/j.pbb.2013.02.018 PMID: 23474372

25. Verri WA Jr, Cunha TM, Magro DA, Domingues AC, Vieira SM, Souza GR et al. Role of IL-18 in overt pain-like behaviour in mice. Eur J Pharmacol. 2008; 588: 207–212. doi: 10.1016/j.ejphar.2008.04.010 PMID: 18511039

26. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 1977; 4: 161–174. PMID: 564014

27. Cunha TM, Verri WA Jr, Vivancos GG, Parada CA et al. An electronic pressure nociception paw test for mice. Braz J Med Biol Res. 2004; 37: 401–407. PMID: 15060710

28. Derrien M, Noble F, Maldonado R, Roques BP. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neurosci Lett. 1993; 160: 193–196. PMID: 8247353

29. Bradley PP, Christensen RD, Rothstein G. Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood. 1982; 60: 618–622. PMID: 6286012

30. Campanini MZ, Pinho-Ribeiro FA, Ivan AL, Ferreira VS, Viilema FM, Vicentini FT et al. Efficacy of topical formulations containing Pimenta psuedocaryophyllus extract against UVB-induced oxidative stress and inflammation in hairless mice. J Photochem Photobiol B. 2013; 127C: 153–160.

31. Borghi SM, Zarpelon AC, Pinho-Ribeiro FA, Cardoso RD, Martins-Pinge MC, Tatakihara Rl et al. Role of TNF-α/TNFFR1 in intense acute swimming-induced delayed onset muscle soreness in mice. Physiol Behav. 2014; 128: 277–287. doi: 10.1016/j.physbeh.2014.01.023 PMID: 24518865

32. Hohmann MSN, Cardoso RD, Pinho-Ribeiro FA, Crespigio J, Cunha TM, Alves-Filho JC et al. 5-Lipoxygenase Deficiency Reduces Acetaminophen-Induced Hepatotoxicity and Lethality. Biomed Res Int. 2013; 13.

33. Cunha TM, Verri WA Jr, Silva JS, Poole S, Ferreira SH, Cunha FQ. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci U S A. 2005; 102: 1755–1760. PMID: 15665080

34. Verri WA Jr, Cunha TM, Poole S, Ferreira SH, Cunha FQ. Cytokine inhibitors and pain control. Rev Bras Reum. 2007; 47: 341–353.

35. Wang ZQ, Porreca F, Cuzzoccra S, Galen K, Lightfoot R, Masini E et al. A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther. 2004; 309: 869–878. PMID: 14988418

36. Binshtok AM, Wang H, Zimmermann K, Cassandre F, Brenner GJ et al. Nociceptors are interleukin-1β receptors. J Neurosci. 2008; 28: 14062–14073. doi: 10.1523/JNEUROSCI.3795-08.2008 PMID: 19109489

37. Jin X, Gereau RW. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J Neurosci. 2006; 26: 246–255. PMID: 16399694

38. Khanna D, Tsevat J. Health-related quality of life—an introduction. Am J Manag Care. 2007; 13 Suppl 9: S218–23. PMID: 18095785

39. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006; 7: 797–809. PMID: 16988655

40. Gulyás B, Halldin C, Sovágó J, Sandell J, Cselényi Z, Vas A et al. Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur J Nucl Med Mol Imaging. 2002; 29: 1031–1038. PMID: 12173017

41. Lohmann A, Dingler E, Sommer W, Schaffler K, Weber W, Schmidt W. Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung. 1992; 42: 914–917. PMID: 1418055
42. El-Laithy HM, Shoukry O, Mahran LG. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm. 2011; 77: 43–55. doi: 10.1016/j.ejpb.2010.10.011 PMID: 21056658

43. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain. 1987; 30: 103–114. PMID: 3614974

44. Cai Y, Li JD, Yan C. Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun. 2013; 434: 439–443. doi: 10.1016/j.bbrc.2013.03.092 PMID: 23583194

45. Zhuang J, Peng W, Li H, Lu Y, Wang K, Fan F et al. Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice. PLoS One. 2013; 8: e82509. doi: 10.1371/journal.pone.0082509 PMID: 24592929

46. Liu RT, Wang A, To E, Gao J, Cao S, Cui JZ et al. Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells. Exp Eye Res. 2014; 127: 49–58. doi: 10.1016/j.exer.2014.07.003 PMID: 25041941

47. Wang H, Zhang K, Zhao L, Tang J, Gao L, Wei Z. Anti-inflammatory effects of vinpocetine on the functional expression of nuclear factor-kappa B and tumor necrosis factor-alpha in a rat model of cerebral ischemia-reperfusion injury. Neurosci Lett. 2014; 566: 247–251. doi: 10.1016/j.neulet.2014.02.045 PMID: 24598438

48. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2: 675–680. PMID: 11477402

49. Ojha D, Mukherjee H, Mondal S, Jena A, Dwivedi VP, Mondal KC et al. Anti-inflammatory activity of Odina wodier Roxb, an Indian folk remedy, through inhibition of toll-like receptor 4 signaling pathway. PLoS One. 2014; 9: e104939. doi: 10.1371/journal.pone.0104939 PMID: 25153081

50. Bhattacharya S, Gill R, Chen ML, Zhang F, Linhardt RJ, Dudeja PK et al. Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. J Biol Chem. 2008; 283: 10550–10558. doi: 10.1074/jbc.M708833200 PMID: 18252714

51. Calil IL, Zarpelon AC, Guerrero ATG, Alves-Filho JC, Ferreira SH, Cunha FQ et al. Lipopolysaccharide induces inflammatory hyperalgesia triggering a TLR4/MyD88-dependent cytokine cascade in the mice paw. PLoS One. 2014; 9: e90013. doi: 10.1371/journal.pone.0090013 PMID: 24595131

52. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004; 6: 203–208. PMID: 15380510

53. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci. 2005; 1056: 218–233. PMID: 16387690

54. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010; 1799: 775–787. doi: 10.1016/j.bbagrm.2010.05.004 PMID: 20493977

55. De Stefano D, Coletta C, Bianca Rd, Falcone L, d’Angelo I, Ungaro F et al. A decoy oligonucleotide to NF-κB delivered through inhalable particles prevents LPS-induced rat airway inflammation. Am J Respir Cell Mol Biol. 2013; 49: 288–295. doi: 10.1165/rcmb.2012-0473OC PMID: 23590300

56. Kernacki KA, Barrett RP, Hobden JA, Hazlett LD. Macrophage inflammatory protein-2 is a mediator of polymorphonuclear neutrophil influx in ocular bacterial infection. J Immunol. 2000; 164: 1037–1045. PMID: 10623858

57. Ward PA. Role of complement, chemokines, and regulatory cytokines in acute lung injury. Ann N Y Acad Sci. 1996; 796: 104–112. PMID: 8906217

58. Miller LS, Pietras EM, Uricchio LH, Hirano K, Rao S, Lin H et al. Inflammasome-mediated production of IL-1β is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol. 2007; 179: 6933–6942. PMID: 17982084

59. Suna TM, Verri WA Jr, Schivo IR, Napimoga MH, Parada CA, Poole S et al. Crucial role of neutrophils in the development of mechanical inflammatory hypernociception. J Leukoc Biol. 2008; 83: 824–832. doi: 10.1189/jlb.0907654 PMID: 18203872

60. Silva MT. Neutrophils and macrophages work in concert as inducers and effectors of adaptive immunity against extracellular and intracellular microbial pathogens. J Leukoc Biol. 2010; 87: 805–813. doi: 10.1189/jlb.1109767 PMID: 2101444
62. Valério DA, Georgetti SR, Magro DA, Casagrande R, Cunha TM, Vicentini FT et al. Quercetin reduces inflammatory pain: Inhibition of oxidative stress and cytokine production. J Nat Prod. 2009; 72: 1975–1979. doi: 10.1021/np900259y PMID: 19899776

63. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain. 2011; 152: S2–S15. doi: 10.1016/j.pain.2010.09.030 PMID: 20961885

64. Janes K, Neumann WL, Salvemini D. Anti-superoxide and anti-peroxynitrite strategies in pain suppression. Biochim Biophys Acta. 2012; 1822: 815–821. doi: 10.1016/j.bbadis.2011.12.008 PMID: 22200449

65. Miyamoto M, Murphy TH, Schnaar RL, Coyle JT. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther. 1989; 250: 1132–1140. PMID: 2778712

66. Sitges M, Sanchez-Tafolla BM, Chiu LM, Aldana BI, Guarneros A. Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res. 2011; 96: 257–266. doi: 10.1016/j.epilepsyres.2011.06.006 PMID: 21737246

67. Gómez CD, Buijs RM, Sitges M. The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1β and TNF-α expression in rat hippocampus. J Neurochem. 2014; 130: 770–779. doi: 10.1111/jnc.12784 PMID: 24903676

68. Gulyás B, Haldin C, Sandell J, Karlsson P, Sovágó J, Kárpati E et al. PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol Scand. 2002; 106: 325–332. PMID: 12460136

69. Souza GR, Talbot J, Lotufo CM, Cunha FQ, Ferreira SH. Fractalkine mediates inflammatory pain through activation of satellite glial cells. Proc Natl Acad Sci U S A. 2013; 110: 11193–11198. doi: 10.1073/pnas.1307441110 PMID: 23776243

70. Molnár P, Erdő SL. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur J Pharmacol. 1995; 273: 303–306. PMID: 7733739

71. Bónóczi P, Gulyás B, Adam-Vizi V, Nemes A, Kárpati E, Kiss B et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 2000; 53: 245–254. PMID: 11113577

72. Sitges M, Galván E, Nekrassov V. Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int. 2005; 46: 533–540. PMID: 15843047

73. Sitges M, Nekrassov V. Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation. Neurochem Res. 1999; 24: 1585–1591. PMID: 10591410

74. Park CK, Xu ZZ, Berta T, Han Q, Chen G, Liu XJ et al. Extracellular microRNAs Activate nociceptor neurons to elicit pain via TLR7 and TRPA1. Neuron. 2014; 82: 47–54. doi: 10.1016/j.neuron.2014.02.011 PMID: 24698267

75. Hendrich J, Alvarez P, Joseph EK, Chen X, Bogen O, Levine JD. Electrophysiological correlates of hyperalgesic priming in vitro and in vivo. Pain. 2013; 154:2207–2215. doi: 10.1016/j.pain.2013.07.004 PMID: 23831864

76. Zelles T, Franklin L, Koncz I, Lendvai B, Zsilla G. The nootropic drug vinpocetine inhibits veratridine-induced [Ca2+]-increase in rat hippocampal CA1 pyramidal cells. Neurochem Res. 2001; 26: 1095–1100. PMID: 11699936

77. Yan C, Zhao AZ, Bentley JK, Beavo JA. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem. 1996; 271: 25699–25706. PMID: 8810348

78. Tessorelli C, Blandini F, Greco R, Nappi G. Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. J Chem Neuroanat. 2004; 27: 23–32. PMID: 15036360

79. Duarte ID, Ferreira SH. The molecular mechanism of central analgesia induced by morphine or carbamol and the L-arginine-nitric oxide-cGMP pathway. Eur J Pharmacol. 1992; 221: 171–174. PMID: 1333972

80. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature. 1988; 334: 698–700. PMID: 3137474

81. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol. 1992; 107: 660–664. PMID: 1472964

82. Kassuya CAL, Ferreira J, Claudino RF, Calixto JB. Intraplantar PGE2 causes nociceptive behaviour and mechanical allodynia: the role of prostanoid E receptors and protein kinases. Br J Pharmacol. 2007; 150: 727–737. PMID: 17310141

83. Parada CA, Reichling DB, Levine JD. Chronic hyperalgesic priming in the rat involves a novel interaction between cAMP and PKCepsilon second messenger pathways. Pain. 2005; 113: 185–190. PMID: 15821379
84. Motoyoshi S, Yamamoto Y, Munesue S, Igawa H, Harashima A, Saito H et al. cAMP ameliorates inflammation by modulation of macrophage receptor for advanced glycation end-products. Biochem J. 2014; 463: 75–82. doi: 10.1042/BJ20140084 PMID: 24995813

85. Korhonen R, Hommo T, Keränne T, Laavola M, Hamalainen M, Vuolteenaho K et al. Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. Br J Pharmacol. 2013; 169: 1525–1536. doi: 10.1111/bph.12189 PMID: 23849041

86. Wu SN, Li HF, Chiang HT. Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. Biochem Pharmacol. 2001; 61: 877–892. PMID: 11274974

87. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des. 2002; 8: 1255–1296. PMID: 12052219

88. Dunkern TR, Hatzelmann A. Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J. 2007; 274: 4812–4824. PMID: 17697115

89. Nosálová V, Machová J, Babulová A. Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung. 1993; 43: 981–985. PMID: 8240463

90. Otroshchenko NP. [Psychopharmacotherapy in combine treatment of depressive disorders in patients with brain pathology affected by the Chernobyl Atomic Electric Power Station accident]. Lik Sprava. 2000: 8–10. PMID: 11452930